A PHASE 2, MULTICENTER, RANDOMIZED STUDY OF TRASTUZUMAB ERUXTECAN IN HER2-MUTATED METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) [DESTINY-LUNG02]
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
Outpatient CTRC
University of Colorado Hospital
Study ID
Protocol Number: 21-2686
More information available at ClinicalTrials.gov: NCT04644237
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers